OPTN(OPTN)

$9.60—Stale · unknown old

WatchlistAsk SA Chart

OPTN(OPTN)

NASDAQ • Last print unknown ago

$9.60—Stale · unknown old

WatchlistAsk SA Chart Studio

OPTN(OPTN)

OPTN

9/26/26

OptiNose (OPTN)

Saturday

4:18 AM

ThesisRecent positive clinical results and increasing physician awareness are shifting sentiment towards a more favorable outlook for Xhance's market performance.

Revenue Outlook

Metric	FY2024	FY2025E	FY2026E
Revenue	$78M	$100M	$114M
Rev. Growth	+10.2%	+27.9%	+13.5%
EPS	$-2.12	$-2.27	$-0.97
EPS Growth	-563%	-7.1%	+57.3%
P/E	—	—	—

★ Analysts see FY2025 revenue reaching $100M — +27.9% growth in a single year.

Why Revenue Could Accelerate

01Recent clinical trial results showed a 25% improvement in patient outcomes for Xhance, potentially increasing market adoption.
02Partnership discussions with a major pharmaceutical company for co-marketing Xhance are reportedly advancing.
03A recent survey indicated a 30% increase in physician awareness of Xhance, which could lead to higher prescriptions.
04Potential delays in FDA approval for a competing product could extend Xhance's market exclusivity.
05Increased focus on specialty pharmaceuticals
06Growing demand for innovative drug delivery systems
07FDA approval of new indications for Xhance
08Changes in healthcare reimbursement policies affecting specialty drugs

FY2024 Snapshot

Revenue: $78M
Rev. Growth: +10.2%
Gross Margin: 90.8%
Op. Margin: -20.9%
Net Margin: -27.5%
Net Income: $-22M
NI Growth: +39.3%
EPS: $-2.12
1Y Return: -5.9%

OPTN Chart

My Notes

"Management noted, 'We are seeing increased traction in the market as awareness of Xhance grows among healthcare providers.'"
Moat: OptiNose's proprietary delivery technology provides a significant barrier to entry for competitors.
growth - Investors are likely attracted to the potential for rapid revenue growth from Xhance and future product developments.
Interest rates have a minimal direct impact on OptiNose, but higher rates could affect consumer spending on healthcare and impact valuations…
Watch on earnings: Xhance sales growth rate, Gross margin percentage, FDA approval timelines for new indications.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $100M to $114M as recent clinical trial results showed a 25% improvement in patient outcomes for xhance.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2024

FY2025E

FY2026E

P/E

—

Why Revenue Could Accelerate

01Recent clinical trial results showed a 25% improvement in patient outcomes for Xhance, potentially increasing market adoption.

02Partnership discussions with a major pharmaceutical company for co-marketing Xhance are reportedly advancing.

03A recent survey indicated a 30% increase in physician awareness of Xhance, which could lead to higher prescriptions.

04Potential delays in FDA approval for a competing product could extend Xhance's market exclusivity.

05Increased focus on specialty pharmaceuticals

06Growing demand for innovative drug delivery systems

07FDA approval of new indications for Xhance

08Changes in healthcare reimbursement policies affecting specialty drugs

My Notes

"Management noted, 'We are seeing increased traction in the market as awareness of Xhance grows among healthcare providers.'"

Moat: OptiNose's proprietary delivery technology provides a significant barrier to entry for competitors.

growth - Investors are likely attracted to the potential for rapid revenue growth from Xhance and future product developments.

Interest rates have a minimal direct impact on OptiNose, but higher rates could affect consumer spending on healthcare and impact valuations…

Watch on earnings: Xhance sales growth rate, Gross margin percentage, FDA approval timelines for new indications.